关于阿尼鲁单抗用于系统性红斑狼疮及临床实践中高未满足需求患者的观点
系统性红斑狼疮(SLE)异质性强、 flares 不可预测,许多患者经标准治疗(SoC)无法达到缓解或狼疮低疾病活动状态(LLDAS)。近期获批的I型干扰素受体拮抗剂阿尼鲁单抗为这类患者提供新选择,3期试验中阿尼鲁单抗组达到DORIS缓解和LLDAS的比例高于安慰剂组。本文基于专家经验提出四类可考虑阿尼鲁单抗的患者类型。
要点
- SLE患者经SoC常无法达到缓解或LLDAS,存在高度未满足需求。
- 3期试验中阿尼鲁单抗组达到DORIS缓解和LLDAS的比例高于安慰剂组。
- 本文提出四类可考虑阿尼鲁单抗的患者:早期高危特征、无法达到LLDAS、无法维持LLDAS、希望减少或停用SoC。
核心结论
- 这些高未满足需求的患者在SoC基础上加用阿尼鲁单抗可能获益,以达到或维持LLDAS或DORIS缓解的治疗目标。
研究设计与样本
- 本文为观点文章,基于专家个人临床经验并结合数据,讨论四类可考虑阿尼鲁单抗治疗的SLE患者类型。
主要发现
- 3期试验中,阿尼鲁单抗组达到DORIS缓解和LLDAS的患者比例高于安慰剂组。
- 阿尼鲁单抗的真实世界临床经验仍有限。
关键数值与推荐
- 可考虑阿尼鲁单抗的四类患者基于:(1)疾病早期高危特征;(2)无法达到至少LLDAS;(3)无法维持至少LLDAS;(4)希望减少或停用SoC。
临床怎么用
- 在真实世界研究结果和更新治疗指南可及之前,由数据支持的专家个人临床经验可能有助于临床决策。
- 作者认为,这些高未满足需求的患者在SoC基础上加用阿尼鲁单抗可能获益,以达到或维持LLDAS或DORIS缓解。
局限性
- 阿尼鲁单抗的真实世界临床经验仍有限。
- 在真实世界研究结果和更新治疗指南可及之前,仅能依据专家个人临床经验并结合数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterised by unpredictable flares. Many patients with SLE are unable to achieve the recommended treatment goal of remission or the intermediate, yet still clinically beneficial, goal of Lupus Low Disease Activity State (LLDAS) with standard of care (SoC) treatments. LLDAS is an emerging treat-to-target goal in SLE with the aim of reducing organ damage and mortality. A high unmet need remains in SLE and mainstay glucocorticoid treatment is associated with unacceptable toxicity. The recently approved type I interferon receptor antagonist anifrolumab is a new treatment option for this historically underserved patient population. In phase 3 trials, a higher percentage of patients on anifrolumab achieved remission, as defined by the Definition Of Remission In SLE (DORIS), and LLDAS compared with placebo. Real-world clinical experience with anifrolumab use is still limited. Until real-world study results and updated treatment guidelines are available, personal expert clinical experience supported by data may inform clinical decision-making. This viewpoint article discusses four example patient types that could be considered for anifrolumab treatment based on (1) high-risk features early in the disease course, (2) inability to achieve and (3) maintain at least LLDAS, or (4) a desire to reduce or stop SoC. These patients with high unmet need may benefit from the addition of anifrolumab to SoC to achieve or maintain the therapeutic goals of LLDAS or DORIS remission.
引用
- Tanaka Y. Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice. RMD Open. 2023. PMID: 37597847. doi:10.1136/rmdopen-2023-003270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。